Thyrocare Technologies Ltd

Q1 FY27Healthcare Services

Thyrocare Technologies Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹578

Market cap₹8.8K Cr

P/E49.0

Updated23 Sept 2026

Read4 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth

MarginMargins steady

CapexCapex planned

The short version

Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn. Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.

From Thyrocare Technologies Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth

Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn.
Medium-term specialty segment (genomics, allergy) expected to form 15-20% of portfolio within 3-5 years.
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth.
Revenue growth target for the company is conservatively around mid to high teens percentage annually.
New franchisee additions and field force expansions to support volume growth and market penetration in Tier 3 and 4 cities.
Emphasis on higher-value, semi-specialized tests expected to improve realization and margins.

2 more points management made on revenue & sales performance

Profitability & Margins

Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.
Specialty segment (genomics, allergy testing) expected to grow to 15%-20% of portfolio in 3-5 years with margins more or less in line with current EBITDA margins.
EBITDA margin improved to 32.2% in Q1 FY27 with 34% YoY growth in EBITDA and PAT, reflecting earnings momentum.
Earnings per share (EPS) grew 34% YoY to INR 3.23 in Q1 FY27; consistent strong EPS growth is expected given current trajectory.
Operating efficiencies and cost control alongside new franchise additions should leverage margins and profits.

2 more points management made on profitability & margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.
Future capex on specialty testing is expected to be limited, mostly expansion CAPEX if volumes exceed expectations.
No significant capex anticipated for specialty segment in the next year.
Thyrocare plans to enter the consumables space with Thyrocare branded consumables (not backward integration); an announcement is expected by September.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There are no current plans for an IPO of API Holding; reports of such are unfounded and speculative.
The API Group is focused on reducing debt from INR1,700 crores to INR1,050 crores and improving profitability before considering any IPO or corporate action.
Discussions on fundraising via equity (IPO) or other methods will only be considered after API becomes profitable ex-Thyrocare and is debt-free, which is at least 12 months away.
Thyrocare Technologies Limited has not provided any specific guidance on new fundraising through debt or equity at this time.

2 more points management made on fundraising & capital structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected orderbook or pending orders for Thyrocare Technologies Limited. However, some relevant insights include: - The company continues to add franchisees, with guidance of approximately 1,700 additions in FY27 (700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4), though some churn is expected. - Franchisee growth is a key driver of volume and revenue expansion. - Ongoing investments in field force and technical sales teams to expand reach and penetrate specialty segments.

2 more points management made on order book & pipeline

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Krsnaa Diagnost. (Q1 FY27)
. Key concall takeaways from Krsnaa Diagnost.'s Q1 FY27 earnings call — and how it ranks against sector peers.
Artemis Medicare (Q1 FY27)
Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years. Key concall takeaways from Artemis Medicare's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q1 FY27 results?

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 49.0 with a market cap of ₹8,846 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.